Literature DB >> 6539092

Biliary excretion of aztreonam in patients with biliary tract disease.

O V Martinez, J U Levi, R G Devlin.   

Abstract

The biliary excretion of aztreonam was studied in 10 post-cholecystectomy patients with T-tube biliary drainage (group A) and four other subjects with obstructive biliary tract disease who had recent placement of external biliary drainage (group B). Maximum biliary levels ranged from 9.7 to 88.2 micrograms/ml (mean, 42.9 +/- 7.9 micrograms/ml) and occurred 2.4 h after injection of a single 1-g dose intravenously. Peak biliary levels observed in group B patients were approximately one-third those in group A. Cumulative 12-h biliary excretion (group B) accounted for 0.18 +/- 0.06% of the total dose. In the same period, urinary excretion accounted for 65 to 72% of the total dose. The lower biliary levels of aztreonam observed in group B patients relative to those in group A suggest that in patients with total biliary tract obstruction the liver may not recover full secretory capacity, at least within 3 to 7 days after biliary decompression.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6539092      PMCID: PMC185517          DOI: 10.1128/AAC.25.3.358

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Cefuroxime concentrations in serum, urine and bile: pharmacokinetic profile.

Authors:  J M Brogard; J Kopferschmitt; M Pinget; J P Arnaud; J Lavillaureix
Journal:  Proc R Soc Med       Date:  1977

2.  Biliary excretion of ampicillin, metampicillin and carbenicillin.

Authors:  M Pinget; J M Brogard; J Dauchel; J Lavillaureix
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

3.  Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects.

Authors:  E A Swabb; M A Leitz; F G Pilkiewicz; A A Sugerman
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

4.  Cefotaxime and desacetyl cefotaxime in human bile.

Authors:  F Kees; E Strehl; P Dominiak; H Grobecker; K Seeger; G Seidel; B Neuhaus; L Safrany
Journal:  Infection       Date:  1983 Mar-Apr       Impact factor: 3.553

5.  Biliary tract excretion of cefazolin, cephalothin, and cephaloridine in the presence of biliary tract disease.

Authors:  K R Ratzan; C Ruiz; G L Irvin
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

6.  Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile.

Authors:  K R Ratzan; H B Baker; I Lauredo
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

7.  Metabolism and pharmacokinetics of aztreonam in healthy subjects.

Authors:  E A Swabb; S M Singhvi; M A Leitz; M Frantz; A Sugerman
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

8.  Biliary excretion of a new semisynthetic cephalosporin, cephacetrile.

Authors:  J M Brogard; P Haegele; M Dorner; J Lavillaureix
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

9.  Biliary concentrations of piperacillin in patients undergoing cholecystectomy.

Authors:  J A Giron; B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

Review 10.  A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic.

Authors:  H C Neu
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

View more
  14 in total

1.  Diagnosis and management of acute cholangitis.

Authors:  Patrick Mosler
Journal:  Curr Gastroenterol Rep       Date:  2011-04

2.  Decreased biliary excretion of cefamandole after percutaneous biliary decompression in patients with total common bile duct obstruction.

Authors:  J U Levi; O V Martinez; T I Malinin; R Zeppa; A Livingstone; D Hutson; P Calhoun
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

3.  Effect of aztreonam on the colon microflora in patients undergoing colorectal surgery.

Authors:  L Kager; B Brismar; A S Malmborg; C E Nord
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

4.  Pharmacokinetics and clinical study of cefotetan in bile: prophylactic use in biliary tract surgery.

Authors:  P Cherrier; P Perrin; S Gueye; A M Bosio; P Tinel; P Blot; R Richer; F Fauvelle
Journal:  Pharm World Sci       Date:  1993-04-23

5.  Antimicrobial therapy for acute cholangitis: Tokyo Guidelines.

Authors:  Atsushi Tanaka; Tadahiro Takada; Yoshifumi Kawarada; Yuji Nimura; Masahiro Yoshida; Fumihiko Miura; Masahiko Hirota; Keita Wada; Toshihiko Mayumi; Harumi Gomi; Joseph S Solomkin; Steven M Strasberg; Henry A Pitt; Jacques Belghiti; Eduardo de Santibanes; Robert Padbury; Miin-Fu Chen; Giulio Belli; Chen-Guo Ker; Serafin C Hilvano; Sheung-Tat Fan; Kui-Hin Liau
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-01-30

6.  Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines.

Authors:  Masahiro Yoshida; Tadahiro Takada; Yoshifumi Kawarada; Atsushi Tanaka; Yuji Nimura; Harumi Gomi; Masahiko Hirota; Fumihiko Miura; Keita Wada; Toshihiko Mayumi; Joseph S Solomkin; Steven Strasberg; Henry A Pitt; Jacques Belghiti; Eduardo de Santibanes; Sheung-Tat Fan; Miin-Fu Chen; Giulio Belli; Serafin C Hilvano; Sun-Whe Kim; Chen-Guo Ker
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-01-30

Review 7.  Clinical pharmacokinetics of aztreonam. An update.

Authors:  H Mattie
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

8.  Decreased biliary excretion of piperacillin after percutaneous relief of extrahepatic obstructive jaundice.

Authors:  J I Blenkharn; N Habib; D Mok; L John; G A McPherson; R N Gibson; L H Blumgart; I S Benjamin
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

Review 9.  Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

10.  Effects of cirrhosis on kinetics of aztreonam.

Authors:  C M MacLeod; E A Bartley; J A Payne; E Hudes; K Vernam; R G Devlin
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.